PD-L1 NEGATIVE

Clinical trials for PD-L1 NEGATIVE explained in plain language.

Never miss a new study

Get alerted when new PD-L1 NEGATIVE trials appear

Sign up with your email to follow new studies for PD-L1 NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New combo attack on Tough-to-Treat breast cancer

Disease control Recruiting now

This study is testing whether adding an immunotherapy drug (pembrolizumab) to a targeted chemotherapy drug (sacituzumab govitecan) works better than the chemotherapy drug alone. It is for people with a specific, hard-to-treat type of advanced breast cancer (triple-negative and PD…

Matched conditions: PD-L1 NEGATIVE

Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated Mar 30, 2026 14:29 UTC

PD-L1 NEGATIVE

Get alerted when new PD-L1 NEGATIVE trials appear

New combo attack on Tough-to-Treat breast cancer